BioSpace News Archive

OMNISOL® goes beyond simply disinfecting to provide long-lasting protection from dangerous pathogens during the pandemic, flu season and beyond

Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first-ever image-guided, catheter-based system for the diagnosis and treatment of Peripheral Artery Disease (PAD), today announced the company has received an extension until May 19, 2021 to regain compliance with the Nasdaq minimum bid price requirement for continued listing.

St. Croix Hospice, a Midwest leader in hospice care, announces its innovative new InTouch Family Connection Program.

Crossover Health, a virtual-first, national medical group, today announced that Chief Executive Officer and Co-Founder, Scott Shreeve, M.D., will give a company update and participate in the “Primary Care v2.0" panel on December 3, 2020 at 12:00 p.m. Eastern.

Caresyntax, a pioneer in surgical automation, analytics, and AI software and technologies, announced an agreement with the University of Iowa Health Care to help improve the safety and efficiency of surgeries performed at the university medical center.

SK Life Science, Inc., a subsidiary of SK Biopharmaceuticals Co., Ltd., an innovative global pharmaceutical company focused on developing treatments for central nervous system (CNS) disorders, will present the latest data on its anti-seizure medication (ASM) cenobamate at the American Epilepsy Society AES2020 Virtual Event,

Newomics Inc., a biotechnology company developing and commercializing mass spectrometry solutions for molecular detection applications, today announced the closing of their $7.9 million Series B financing, led by MSA Capital. Joining the round are new investor LDV Partners, and existing Series A investors, including the Berkeley Catalyst Fund and the Photon Fund. Daojing Wang, Ph.D., Newomics’ founder and CEO, says

Clinical stage pharmaceutical company forms multi-national research consortium to establish iron chelating compounds as disease modifying therapy for Parkinson’s

Sight Sciences, Inc., a growth-stage medical device company transforming the two fastest growing segments in ophthalmology and optometry, glaucoma and dry eye disease, announced the closing of its Series F Preferred Stock financing led by D1 Capital Partners and new equity partner Janus Henderson Investors.

Codagenix Inc., a clinical-stage biotechnology company developing prophylactic vaccines and oncolytic virus therapies, announced today the completion of dosing in a Phase 1 clinical trial of its live attenuated CodaVax™-RSV vaccine, an intranasally-administered vaccine for the prevention of respiratory syncytial virus (RSV).